Replies to post #98612 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I noticed Dr. Schwartz emphasized how important it was to obtain post-progression images as well. If this is being used informally in the Phase III trial for image interpretation review, that could explain some delay.

Especially because I think everyone in the field are fast becoming aware that immunoncology treatments require an ever-evolving criteria assessment.